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ABSTRACT
Dissemination of antibiotic resistance in bacteria is associated with prescription of the corresponding
drugs. Various pharmacokinetic–pharmacodynamic parameters have been developed with the
intention of reducing the spread of resistance. In this review, it is considered whether dosing
regimens based on these parameters can delay this spread. The evolution of bacterial resistance to
antibiotics involves two successive but distinct and independent mechanisms. The ﬁrst occurs by
mutation in the genome, including the host chromosome and mobile accessory genetic elements such
as plasmids or transposons, or, following acquisition of a resistance determinant from another
bacterium, by horizontal gene transfer. These two genetic events happen by chance, which means that
they do not rely on the presence of an antibiotic in the environment; that is, they are not induced, but
simply revealed and propagated by the drugs. The second step is dissemination of resistance which
can be due to the spread of bacteria (clonal epidemics), of replicons (plasmid epidemics) or of
resistance determinants (gene epidemics). Resistance dissemination by each one of these three levels
which superimpose in nature, is not only infectious but also exponential, since all three are associated
with DNA replication (duplication) of the host chromosome, of a plasmid, or of a transposon. As
opposed to emergence, dissemination is clearly associated with the selective pressure exerted by
antibiotic prescription [1,2]. The consequence of this dual evolutionary pathway is that proper use of
antibiotics will, at best, delay the spread of resistance. In this review, the pharmacokinetic–
pharmacodynamic (PK–PD) parameters that are intended to lower resistance dissemination are
considered exclusively.
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COMMON-SENSE ACRONYMS
Two notions have been introduced into the ﬁeld of
pharmacokinetics–pharmacodynamics (PK–PD),
with the intent of ﬁghting resistance (for a recent
review, see Ref. [3]): the mutation prevention
concentration (MPC) and the mutation selection
window (MSW) (Fig. 1). The MPC, as its name
indicates, is the concentration of antibiotic that
prevents selection (not of emergence, as already
discussed) of resistant mutants. What this acro-
nym actually means is that, to kill a bacterium,
what is needed is more antibiotic than the lowest
concentration that would inhibit this bacterium
(a value known as the minimal inhibitory concen-
tration, MIC)—a rather obvious statement! Thus,
and as its name does not indicate, the MPC
corresponds to the MIC of the mutant. In the case
of stepwise acquisition of resistance by successive
mutations, one then ends up with MPC1, MPC2,
etc., which correspond, respectively, to theMICs of
ﬁrst-step, second-step, etc. mutants. The MSW is
the range of antibiotic concentrations that opti-
mally favours growth of the resistant mutants.
These concentrations range from sub-MIC (close to
MIC) values for the susceptible parental strain to
the MIC for the mutant derivatives, the so-called
MPC. This is a notion that has been known for a
very long period of time and has been exploited by
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geneticists in 56-year-old techniques [4]. As with
MPCs, there are MSW1, MSW2, etc.
According to this ‘concept’, in a treated infec-
tion, the bacteria spend their time watching at the
window, so to speak, the susceptible bacteria at
MSW1, the ﬁrst-step mutants at MSW2, the
second-step mutants at MSW3, and so on.
THE SUBTLE CHARMS OF
ACRONYMS
The notions of MPC and MSW were rediscovered
a` propos the very simple and narrow system of
ﬂuoroquinolone resistance by mutational alter-
ation of the drug targets, the type II topoisome-
rases, DNA gyrase and topoisomerase IV [5].
Even in this over-simplistic system, it has recently
been shown that selection of resistant commensals
during therapy is not preventable by optimizing
the dosing regimen (47th Interscience Conference
on Antimicrobial Agents and Chemotherapy
2007, abstract 585). These two acronyms cannot
even be applied to Gram-negative bacteria,
because of plasmid-mediated resistance to this
class of molecules through target protection [6,7],
inactivation [8] or efﬂux [9].
In this simplistic resistance system, there is an
inﬁnite number of MPCs! This is due to:
1 The multiplicity of quinolones, which differ in
their intrinsic activity. A resistance mechanism
has no intrinsic value; it simply increases the
concentration of antibiotic at which the bacte-
rium is inhibited. Thus, the more active the
ﬂuoroquinolone, the lower the level of
resistance of a given type of mutant, and thus
the lower the drug concentrations that corre-
spond to the MPC [10].
2 The multiplicity of bacterial species that differ
in their susceptibility to a given antibiotic. For
example, the MIC of ciproﬂoxacin for Pseudo-
monas aeruginosa (0.5 mg ⁄L) is clearly very
different from that for Neisseria meningitidis
(0.0015 mg ⁄L). This implies that MPCs are not
only genus-speciﬁc but even species-speciﬁc.
They are, in fact, strain-speciﬁc!
3 The fact that the activity of antibiotics is
determined in vitro on planctonic cells,
whereas they often generate bioﬁlms in vivo.
This change in lifestyle can greatly affect
bacterial susceptibility to antibiotics and is
not taken into account in the PK–PD approach.
4 The fact that, as is increasingly being shown, a
large number of bacteria can be, at least
transiently, located intracellularly, where the
antibiotic concentrations are clearly distinct
from those in the extracellular compartments,
an observation that should also be taken into
consideration.
5 The commensal ﬂora adding to this already
complicated situation. When one treats a
patient infected with a pathogenic bacterium
with an antimicrobial agent, although therapy
is intended to eradicate the pathogen, the
antibiotic acts on the entire ﬂora of the patient;
in particular, in the case of oral administration,
high concentrations of drugs are in contact
with the gigantic population of commensals in
the digestive tract. It has been recently
proposed that resident gut bacteria could act
as a reservoir of resistance for more
pathogenic species [11]. It would thus be
advisable to determine MPC–MSW values for
digestive commensals, including anaerobes, an
impossible task.
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Fig. 1. Pharmacokinetic curves after
one or two administration(s) of an
antibiotic. MIC, minimal inhibi-
tory concentration; MPC, mutation
prevention concentration; MSW,
mutation selection window; IRD,
induction revolving door.
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6 The MPC–MSW quantiﬁcation relying on anti-
biotic concentrations that are amenable to
dosages, that is, in practice, mainly blood
levels. This is not particularly informative or
useful, insofar as the relevant values are those
at the site of infection, where action takes
place; these are most often inaccessible.
So, not only is there an inﬁnite number of
MPC–MSW values, but PK–PD has also generated
a few additional ‘predictive indices’, such as
Cmax ⁄MIC, Cmax ⁄MPC, time above MPC, and
time at the window. [3]. The mere multiplicity
of these indices indicates that none of them is of
general value.
USELESS ACRONYMS
The uselessness of PK–PD to contribute to the
diminution of resistance is stressed by the
following facts.
1 Colonization of patients by strains that are
already resistant is by far more common than
mutant selection under therapy [10]. An exam-
ple of this is ﬂuoroquinolone resistance in
methicillin-resistant Staphylococcus aureus
(MRSA), and it also accounts for the impact
of the pneumococcal vaccine on antibiotic
resistance in this genus, not only for the
vaccinees, but also for their close contacts [12].
2 Under natural conditions, regulatory mutations
are more frequent, and thus more clinically
relevant, than target mutations [13]. In addi-
tion, the former type of genetic event can
confer nearly a continuum of resistance levels,
depending upon the type or locus of the
mutation [13]. This, in turn, generates a con-
tinuum of MPC–MSWs.
3 Resistance is much more likely to occur
following horizontal gene transfer than by
mutation. Becoming resistant to an antibiotic
corresponds to acquisition of a function by
the bacterium. The price to pay for this new
function is known as the biological cost of
resistance. As bacteria are subjected to the
principle of parsimony, they have to mini-
mize the cost of resistance to maintain a
degree of ﬁtness close to that of the parental
susceptible strain, in order to remain com-
petitive with the susceptible bacterial popu-
lation in the absence of antibiotic. An efﬁcient
and elegant way to maintain ﬁtness is to
harbour an inducible resistance mechanism;
in other words, resistance that will be phe-
notypically expressed exclusively in the pres-
ence of the antibiotic, i.e. when needed [13].
4 An additional observation is resistance by
efﬂux of the drugs. Sequence determination
of the genomes of representatives of multiple
bacterial genera has revealed that they all
encode efﬂux pumps that expel, among other
toxic molecules, antibiotics [14]. Expression of
the structural genes for these pumps, which
can be considered as bacterial kidneys, is
regulated in a tight fashion, positively or
negatively [13]. Clinical isolates that became
resistant by gene overexpression following a
mutation in the regulatory modules for a
pump have been reported [15]. In general,
efﬂux pumps, and in particular members of
the RND superfamily [16], have very broad
substrate ranges, including various drug
classes as well as biocides [17]. Thus, a single
regulatory mutation corresponds to a very
large number of MPCs and MSWs,
rendering impossible the prevention of its
occurrence.
Antibiotic resistance is only transiently useful
to the bacteria. This makes horizontal acquisi-
tion of inducibly regulated genetic information
much more effective in facing the challenge of
an antibiotic in the environment than the occur-
rence of mutations that are, at best, slowly
reversible. Consideration of populations, rather
than individual bacteria, conﬁrms that acquisi-
tion of a mobile accessory genetic element fulﬁls
the requirement for transient (multi)drug resis-
tance. Most unfortunately, neither MPCs nor
MSWs can inﬂuence the rate of transfer by the
mechanisms discussed below, which are in-
creased by the presence of antibiotics in the
bacterial ecosystems.
FACILITATION OF CONJUGATIVE
RESISTANCE TRANSFER
DNA translocation across bacterial membranes
occurs at the early stages of conjugation. The
peptidoglycan of Gram-positive bacteria is
50–100 layers thick. Thus, the cell wall of these
bacteria might constitute an important barrier
for the acquisition of exogenous DNA. Consis-
tently, it has been shown that sub-MIC concen-
trations of penicillins (oxacillin or penicillin G)
in the mating medium results in a 50-fold
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increase of the conjugal transfer of plasmid
DNA from Escherichia coli to S. aureus and
Listeria monocytogenes [18]. Similarly, it has been
reported that low oxacillin concentrations
increase the in vitro frequency of transfer of
the enterococcal conjugative transposon Tn916
from Enterococcus faecalis to Bacillus anthracis
[19]. Penicillins decrease the percentage of
peptidoglycan cross-linkage by inhibition of the
transpeptidases, which might increase cell
permeability and facilitate the formation of
mating aggregates. In addition, cell wall damage
caused by incorporation of cell wall-active
agents into the culture medium similarly
improves the efﬁciency of electro-transformation
of Gram-positive bacteria [17,20–22].
INDUCTION OF CONJUGATIVE
RESISTANCE TRANSFER
Some transposons have evolved such that the
antibiotic to which they confer resistance can
speciﬁcally stimulate their intercellular mobility.
Conjugative transposons (or integrative conjuga-
tive elements) of the Tn916 ⁄Tn1545 family are
widespread in Gram-positive cocci and contain
the tet(M) tetracycline resistance determinant,
either alone (e.g. Tn916) or associated with other
resistance genes (e.g. Tn1545) [23–25]. Exposure
of bacteria harbouring Tn1545 to low concentra-
tions (0.2–1 mg ⁄L) of tetracycline results in a
10-fold to 100-fold increase in its transfer
frequency both in vitro and in the digestive tract
of gnotobiotic mice [26]. This observation has
been conﬁrmed for other elements [27], including
the Tn916 prototype [28]. Similarly, low levels of
tetracycline stimulate the transfer of the Bactero-
ides conjugative Tcr Emr 10 000-fold [29]. By a
totally different molecular mechanism, the SOS
response to DNA damage alleviates repression of
the transfer functions of the c. 100-kb element
SXT. This integrative conjugative element, which
is common in various bacterial species and, in
particular, in Vibrio cholerae, confers resistance to
chloramphenicol, streptomycin, sulphonamides
and trimethroprim. The SOS response can be
triggered by a variety of environmental factors,
including antibiotics, and it has been shown that
SOS response induction by low concentrations of
ﬂuoroquinolones and mitomycin C markedly
enhances the transfer of SXT and related genetic
elements [30].
INDUCTION OF TRANSFORMATION
IN STREPTOCOCCCUS PNEUMONIAE
Natural transformation is the ability of bacteria
that belong to a certain species (Streptococcus
pneumoniae, Acinetobacter spp., Neisseria spp.) and
are in a competent state to pick up naked DNA
from the environment [31]. It has been shown
recently that low concentrations of certain amino-
glycosides or ﬂuoroquinolones can very efﬁ-
ciently induce competence in Streptococcus
pneumoniae in the absence of bacterial killing
[32]. It therefore appears that the stress induced
by antibiotics increases the rate of genetic
exchange, including that of genes mediating
antibiotic resistance. Again, in this transfer sys-
tem, no MPC or MSW can impede enhancement
of the spread of resistance in pneumococci asso-
ciated with antibiotic therapy.
THE INDUCTION REVOLVING DOOR
As already mentioned, the majority of resistance
mechanisms are inducibly expressed. This is the
case, for example, for VanA-type vancomycin
resistance in enterococci [13]. Induction of resis-
tance is due to the presence, upstream from the
resistance genes, of two genes that encode a two-
component regulatory system. This system, which
is very common in bacteria, is responsible for
activation of transcription of the resistance genes,
which occurs at very low concentrations of
vancomycin or teicoplanin. Acquisition by MRSA
of the vanA operon from enterococci led to two
types of VanA-type MRSA [33,34]. One half of the
clinical isolates is resistant to high levels of both
glycopeptides, whereas the remaining half is
resistant to low levels of vancomycin and remains
susceptible to teicoplanin. The latter phenotype is
due to two interlinked phenomena: a high rate of
resistance loss due to plasmid instability, and a
very long delay in induction of resistance, result-
ing in a prolonged lag phase (Fig. 2). This obser-
vation is important because: (i) on an individual
(patient) basis, resistance being inducible, glyco-
peptide therapy will lead to clinical failure;
and (ii) on a community basis, the second type
of strain remains undetected (in particular, by
automated susceptibility systems), and this delays
the implementation of hygiene measures to pre-
vent further spread of these dangerous microor-
ganisms. Therefore, the very low concentration of
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antibiotics at the onset of therapy is crucial for
induction of clinical resistance by various mech-
anisms [13]. Most curiously, these initial and
repeated low levels of antibiotics are ignored in
the PK–PD approach, which is intended to
minimize resistance. Because, as we have seen,
in PK–PD representation the windows are already
occupied, we are left with (and at) the door of the
antibiotic kinetic. I thus propose the notion of
induction door (ID) for this portion of the curve
(Fig. 1). Although the acronym sounds good (and
in fact may well represent the only sensible idea
in this entire story), MIC, MPC and MSW strongly
suggest that, to be successful, an acronym should
comprise three letters. Considering that, during
induction, the antibiotic is neither consumed nor
destroyed but is recycled, I propose the concept of
induction revolving door (IRD).
CONCLUSION
Votre ﬁlle est muette
As we have seen repeatedly in this brief review,
the PK–PD acronyms dealing with antibiotic
resistance are remarkable truisms. They are rem-
iniscent of the famous prototype in the medical
ﬁeld ‘votre ﬁlle est muette’ [35]. In addition, they
introduce confusion by rediscovering old, well-
established and well-accepted notions and by
generating unnecessary acronyms (e.g. MPC for
MIC).
If, as a medical bacteriologist, you are short of
ideas or unable to contribute a new concept to the
ﬁeld, I suggest that you coin an acronym. As I
have tried to point out, the latter does not need to
convey any new notion to be popularized and you
may well end up being remembered.
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